EP0814827A4 - Wachstumsfaktor-b, spezifisch für vaskuläre endothelzellen - Google Patents

Wachstumsfaktor-b, spezifisch für vaskuläre endothelzellen

Info

Publication number
EP0814827A4
EP0814827A4 EP96909573A EP96909573A EP0814827A4 EP 0814827 A4 EP0814827 A4 EP 0814827A4 EP 96909573 A EP96909573 A EP 96909573A EP 96909573 A EP96909573 A EP 96909573A EP 0814827 A4 EP0814827 A4 EP 0814827A4
Authority
EP
European Patent Office
Prior art keywords
endothelial cells
vascular endothelial
growth factor
polypeptides
vegf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP96909573A
Other languages
English (en)
French (fr)
Other versions
EP0814827B1 (de
EP0814827A1 (de
Inventor
Ulf Eriksson
Birgitta Olofsson
Kari Alitalo
Katri Pajusola
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Licentia Oy
Ludwig Cancer Research
Original Assignee
Ludwig Institute for Cancer Research Ltd
Helsinki University Licensing Ltd
Ludwig Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27410265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0814827(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/469,427 external-priority patent/US5607918A/en
Application filed by Ludwig Institute for Cancer Research Ltd, Helsinki University Licensing Ltd, Ludwig Cancer Research filed Critical Ludwig Institute for Cancer Research Ltd
Publication of EP0814827A1 publication Critical patent/EP0814827A1/de
Publication of EP0814827A4 publication Critical patent/EP0814827A4/de
Application granted granted Critical
Publication of EP0814827B1 publication Critical patent/EP0814827B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP96909573A 1995-03-01 1996-03-01 Wachstumsfaktor-b, spezifisch für vaskuläre endothelzellen Expired - Lifetime EP0814827B1 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US569063 1990-08-17
US39765195A 1995-03-01 1995-03-01
US397651 1995-03-01
US08/469,427 US5607918A (en) 1995-03-01 1995-06-06 Vascular endothelial growth factor-B and DNA coding therefor
US08/569,063 US5928939A (en) 1995-03-01 1995-12-06 Vascular endothelial growth factor-b and dna coding therefor
PCT/US1996/002957 WO1996026736A1 (en) 1995-03-01 1996-03-01 Vascular endothelial growth factor-b
US469427 1999-12-23

Publications (3)

Publication Number Publication Date
EP0814827A1 EP0814827A1 (de) 1998-01-07
EP0814827A4 true EP0814827A4 (de) 1999-11-10
EP0814827B1 EP0814827B1 (de) 2003-07-23

Family

ID=27410265

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96909573A Expired - Lifetime EP0814827B1 (de) 1995-03-01 1996-03-01 Wachstumsfaktor-b, spezifisch für vaskuläre endothelzellen

Country Status (14)

Country Link
US (5) US5928939A (de)
EP (1) EP0814827B1 (de)
JP (2) JP3275024B2 (de)
CN (1) CN1146440C (de)
AT (1) ATE245437T1 (de)
AU (1) AU741856B2 (de)
CA (1) CA2211687C (de)
DE (1) DE69629181T2 (de)
DK (1) DK0814827T3 (de)
ES (1) ES2202432T3 (de)
NO (1) NO973933L (de)
NZ (1) NZ305091A (de)
PT (1) PT814827E (de)
WO (1) WO1996026736A1 (de)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US6608182B1 (en) * 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
EP0751992B1 (de) * 1994-03-08 2005-11-09 Human Genome Sciences, Inc. Vaskularer endothelialer wachstumsfaktor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US7160991B1 (en) * 1995-03-02 2007-01-09 Ludwig Institute For Cancer Research Vascular endothelial growth factor polypeptides
JPH11500139A (ja) * 1995-03-02 1999-01-06 アムラド・オペレイションズ・プロプライエタリー・リミテッド 新規成長因子およびそれをコードする遺伝子配列
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
EP0873348A4 (de) * 1995-06-06 2000-11-08 Human Genome Sciences Inc Menschlicher vaskularer endothelialer wachtumsfaktor 3
US7423125B2 (en) * 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
ES2202469T5 (es) 1995-09-08 2011-06-06 Genentech, Inc. Proteína relacionada con el vegf.
WO1997012972A2 (en) 1995-09-29 1997-04-10 Universita'degli Studi Di Siena Regulated genes and uses thereof
AU1116297A (en) 1995-11-08 1997-05-29 Immunex Corporation Flk-1 binding protein
US6994989B1 (en) 1995-11-08 2006-02-07 Immunex Corp. FLK-1 binding proteins
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
CA2263890C (en) 1996-08-23 2013-05-14 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
WO1998024811A2 (en) * 1996-12-06 1998-06-11 Zymogenetics, Inc. Vascular endothelial growth factor
ZA9711456B (en) * 1996-12-20 1998-06-30 Ludwig Inst Cancer Res VEGF-B/receptor complex and uses thereof.
WO1998039035A1 (en) 1997-03-07 1998-09-11 The Wistar Institute Of Anatomy & Biology Method and compositions for healing tissue defects and inducing hypervascularity in mammalian tissue
JP2001524828A (ja) * 1997-04-25 2001-12-04 コラテラル・セラピューティクス 切断型ｖｅｇｆ関連蛋白質
US6281175B1 (en) 1997-09-23 2001-08-28 Scimed Life Systems, Inc. Medical emulsion for lubrication and delivery of drugs
EP1053326A2 (de) 1998-02-06 2000-11-22 Collateral Therapeutics Varianten des angiogenen faktors vaskularer endothelialzell-wachstumsfaktor: vegf
US20030118567A1 (en) * 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
DE19813774A1 (de) * 1998-03-27 1999-09-30 Max Planck Gesellschaft Parapockenvirus-kodierter vaskulärer Endothelzell Wachstumsfaktor (PPV-VEGF)
JP2002534061A (ja) 1998-11-10 2002-10-15 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ 血小板由来増殖因子ｄ、それをコードするｄｎａ、及びその利用法
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
AU3693000A (en) * 1999-01-29 2000-08-18 Licentia Ltd Platelet-derived growth factor/vascular endothelial growth factor-like growth factor h, and uses thereof
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
EP2357192A1 (de) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Menschliches alpha-Endokin und Verfahren zu seiner Verwendung
NZ513780A (en) * 1999-03-03 2001-09-28 Ludwig Inst Cancer Res Heart abnormalities in vascular endothelial growth factor B (VEGF-B) deficient animals and methods relating to these heart abnormalities
AU4662400A (en) * 1999-04-26 2000-11-10 Helsinki University Licensing Ltd Role of vascular endothelial growth factor-b (vegf-b) in developing bones and uses thereof
CA2375617A1 (en) * 1999-06-07 2000-12-14 Edwards Lifesciences Corporation Targeted angiogenesis
WO2001008684A1 (en) * 1999-07-28 2001-02-08 The Board Of Trustees Of The Leland Stanford Junior University Nicotine in therapeutic angiogenesis and vasculogenesis
US8188043B2 (en) * 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
DE60136334D1 (en) * 2000-02-02 2008-12-11 Us Health Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
AUPQ568100A0 (en) * 2000-02-16 2000-03-09 Amrad Operations Pty. Limited A method for producing recombinant molecules
AU2001239884B2 (en) * 2000-02-25 2006-08-10 Vegenics Limited Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins and screening methods for modulators
AUPQ592100A0 (en) * 2000-02-29 2000-03-23 Council Of The Queensland Institute Of Medical Research, The A method of treatment and prophylaxis
US20030104977A1 (en) * 2000-03-31 2003-06-05 Ugo Ripamonti Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
EP1274720A4 (de) 2000-04-12 2004-08-18 Human Genome Sciences Inc Albumin enthaltende fusionsproteine
CA2409948A1 (en) * 2000-05-17 2001-11-22 Xuri Li Methods for detecting for the presence of tumor cells and for screening for anti-tumor agents
CN1461342A (zh) * 2000-07-26 2003-12-10 路德维格癌症研究所 糖基化vegf－b和增加可溶性vegf－b量的方法
US7273751B2 (en) * 2000-08-04 2007-09-25 Human Genome Science, Inc. Vascular endothelial growth factor-2
AU2001296521A1 (en) * 2000-10-02 2002-04-15 St. Elizabeth's Medical Center Of Boston, Inc. Use of lymphangiogenic agents to treat lymphatic disorders
JP2004527462A (ja) * 2000-11-01 2004-09-09 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 血管新生活性のｉｎｖｉｖｏ刺激
AU2884102A (en) * 2000-12-07 2002-06-18 Sangamo Biosciences Inc Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) * 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
US20070111944A1 (en) * 2001-02-16 2007-05-17 Scrofani Sergio D B Purification of vascular endothelial growth factor-B
US20070050857A1 (en) * 2001-02-28 2007-03-01 Hayward Nick K Method of treatment and prophylaxis
AU2002303261A1 (en) * 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
DE60236646D1 (de) 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 Antikörper
AU2002252631A1 (en) * 2001-04-13 2002-10-28 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
WO2002083850A2 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
US7402312B2 (en) * 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
DE60234100D1 (de) * 2001-04-24 2009-12-03 Vlaams Interuniv Inst Biotech Verwendung von "hypoxia inducible factor 2alpha" zur behandlung von "neonatal respiratory distress syndrome"
WO2003000009A2 (en) * 2001-06-20 2003-01-03 Ludwig Institute For Cancer Research Stimulation of vascularization with vegf-b
AU2002319402B2 (en) * 2001-06-28 2008-09-11 Domantis Limited Dual-specific ligand and its use
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
CN1555488A (zh) * 2001-07-12 2004-12-15 路德维格癌症研究院 淋巴管内皮细胞物质及方法
WO2003018752A2 (en) 2001-08-23 2003-03-06 The Wistar Institute Of Anatomy And Biology An organotypic intestinal culture and methods of use thereof
US20030113324A1 (en) 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
US20030221931A1 (en) * 2002-02-28 2003-12-04 Steve Marsh Sliding device
US20040005671A1 (en) * 2002-05-17 2004-01-08 Amrad Operations Pty Ltd. Immunointeractive molecules
AU2003237456A1 (en) * 2002-06-05 2003-12-22 Sopherion Therapeutics, Inc. Method to screen ligands using eukaryotic cell display
EP1912069A3 (de) 2002-06-05 2008-07-09 Sopherion Therapeutics, Inc. Verfahren für Schirmliganden mit eukaryotischer Zellenanzeige
US20030232439A1 (en) * 2002-06-17 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of VEGF-B expression
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
EP1600459A3 (de) * 2002-06-28 2005-12-07 Domantis Limited Ligand
US7479270B2 (en) 2002-07-23 2009-01-20 Vegenics Limited Methods and compositions for activating VEGF-D and VEGF-C
CA2547899C (en) * 2002-12-05 2014-04-15 Case Western Reserve University Cell-based therapies for ischemia
US7470538B2 (en) * 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
JP2006523090A (ja) * 2002-12-27 2006-10-12 ドマンティス リミテッド リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
EP1594527A2 (de) * 2003-02-04 2005-11-16 Ludwig Institute For Cancer Research Vegf-b und pdgf modulierung von stammzellen
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
EP1560025A3 (de) * 2003-10-03 2011-09-07 F. Hoffmann-La Roche AG Marker spezifisch für Diabetes
CA2552241C (en) 2003-12-30 2013-10-01 Durect Corporation Co-polymeric devices for controlled release of active agents
US20050214280A1 (en) * 2004-03-02 2005-09-29 Ludwig Institute For Cancer Research Method for inhibiting tumor formation and growth
WO2005087177A2 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same
WO2005087812A1 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
JP4903689B2 (ja) * 2004-04-08 2012-03-28 サンガモ バイオサイエンシズ インコーポレイテッド 神経障害および神経変性症状を治療するための方法と組成物
EP2476427B1 (de) * 2004-08-02 2018-01-17 Zenyth Operations PTY. Ltd. Verfahren zur Behandlung von Krebs mit einem VEGF-B-Antagonisten
US7595149B1 (en) 2004-11-08 2009-09-29 University Of Kentucky Research Foundation Methods for cancer detection
EP1869075B1 (de) * 2005-02-28 2012-04-11 Sangamo BioSciences, Inc. Antiangiogene methoden und zusammensetzungen
MX2007012766A (es) * 2005-04-12 2008-10-01 Intradigm Corp Composición y métodos de terapéuticos de arni para el tratamiento de cáncer y otras enfermedades de neovascularización.
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
WO2007022287A2 (en) 2005-08-15 2007-02-22 Vegenics Limited Modified vegf and pdgf with improved angiogenic properties
CN101454344A (zh) * 2005-12-01 2009-06-10 杜门蒂斯有限公司 与白细胞介素-1受体1型结合的非竞争性域抗体形式
DK2548578T3 (da) 2006-05-17 2014-10-06 Ludwig Inst Cancer Res Målretning af VEGF-B-regulering af fedtsyretransportører til modulering af humane sygdomme
WO2008085229A2 (en) * 2006-11-15 2008-07-17 Arteriocyte Inc. Cell-based therapies for treating liver disease
NZ580530A (en) * 2007-06-06 2012-04-27 Domantis Ltd Anti vegf polypeptides, antibody variable domains and antagonists
US7819579B2 (en) * 2007-11-26 2010-10-26 Schmulenson Harold K Radiation sensing device and holder
WO2009075565A1 (en) * 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Methods for controlling vasculogenesis
JP5690593B2 (ja) 2007-12-26 2015-03-25 ヴァクシネックス， インコーポレイテッド 抗ｃ３５抗体併用療法および方法
WO2009126698A2 (en) * 2008-04-09 2009-10-15 Ludwig Institute For Cancer Research Regulation of fatty acid transporters
IL205774A0 (en) * 2010-05-13 2010-12-30 Muhammad Abdulrazik Novel compounds for the treatment of glaucoma and ocular hypertension
KR101335203B1 (ko) * 2010-03-26 2013-11-29 숙명여자대학교산학협력단 혈관신생촉진용 펩타이드 및 이의 용도
WO2011154308A1 (en) 2010-06-08 2011-12-15 Proyecto De Biomedicina Cima, S.L. New compositions and cell therapy methods for the treatment of cirrhosis
RU2477529C2 (ru) * 2011-04-28 2013-03-10 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ коррекции эндотелиальной дисфункции раствором гомеопатических разведений антител к эндотелиальной синтазе оксида азота человека
KR102948178B1 (ko) 2013-07-12 2026-04-10 아스텔라스 유에스 엘엘씨 안과적 질환을 치료하거나 예방하기 위한 방법
CN105979965B (zh) * 2013-12-18 2021-07-09 杰特有限公司 治疗伤口的方法
CN107661492A (zh) * 2017-08-31 2018-02-06 中山大学中山眼科中心 Vegf‑b的新用途
CN107537026A (zh) * 2017-08-31 2018-01-05 中山大学中山眼科中心 Vegf‑b的应用
US10745454B2 (en) * 2018-01-31 2020-08-18 Seyed Mohsen Asghari Method of synthesizing antagonist peptides for cell growth
CN109337931A (zh) * 2018-11-02 2019-02-15 东北师范大学 Vegfb基因的应用及vegfb肿瘤诱导和肿瘤抑制动物模型的构建方法
CN110777146A (zh) * 2019-11-28 2020-02-11 南通大学 一种pdgfb启动子活性报告质粒的构建方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990013649A1 (en) * 1989-05-12 1990-11-15 Genentech, Inc. Production of vascular endothelial cell growth factor and dna encoding same
WO1991002058A1 (en) * 1989-07-27 1991-02-21 California Biotechnology Inc. Production of vascular endothelial cell growth factor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659678A (en) * 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4456550A (en) * 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US5036003A (en) * 1987-08-21 1991-07-30 Monsanto Company Antibodies to VPF
US5240848A (en) * 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5726152A (en) * 1990-09-21 1998-03-10 Merck & Co., Inc. Vascular endothelial cell growth factor II
EP0751992B1 (de) * 1994-03-08 2005-11-09 Human Genome Sciences, Inc. Vaskularer endothelialer wachstumsfaktor 2
US5607918A (en) * 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
JPH11500139A (ja) * 1995-03-02 1999-01-06 アムラド・オペレイションズ・プロプライエタリー・リミテッド 新規成長因子およびそれをコードする遺伝子配列
EP0873348A4 (de) * 1995-06-06 2000-11-08 Human Genome Sciences Inc Menschlicher vaskularer endothelialer wachtumsfaktor 3

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990013649A1 (en) * 1989-05-12 1990-11-15 Genentech, Inc. Production of vascular endothelial cell growth factor and dna encoding same
WO1991002058A1 (en) * 1989-07-27 1991-02-21 California Biotechnology Inc. Production of vascular endothelial cell growth factor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CONN, GREG ET AL: "Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor", PROC. NATL. ACAD. SCI. U. S. A. (1990), 87(7), 2628-32, 1990, XP002114935 *
LEUNG, DAVID W. ET AL: "Vascular endothelial growth factor is a secreted angiogenic mitogen", SCIENCE (WASHINGTON, D. C., 1883-) (1989), 246(4935), 1306-9, 1989, XP000083690 *

Also Published As

Publication number Publication date
US20050064493A1 (en) 2005-03-24
DK0814827T3 (da) 2003-11-10
JP2000228982A (ja) 2000-08-22
US5840693A (en) 1998-11-24
US7341996B2 (en) 2008-03-11
AU741856B2 (en) 2001-12-13
ATE245437T1 (de) 2003-08-15
US20030170253A1 (en) 2003-09-11
PT814827E (pt) 2003-11-28
EP0814827B1 (de) 2003-07-23
US5928939A (en) 1999-07-27
DE69629181D1 (de) 2003-08-28
CA2211687A1 (en) 1996-09-06
EP0814827A1 (de) 1998-01-07
WO1996026736A1 (en) 1996-09-06
CN1176603A (zh) 1998-03-18
NZ305091A (en) 1998-11-25
NO973933D0 (no) 1997-08-27
DE69629181T2 (de) 2004-05-13
HK1008485A1 (en) 1999-07-30
AU5302196A (en) 1996-09-18
NO973933L (no) 1997-09-01
JPH10510718A (ja) 1998-10-20
ES2202432T3 (es) 2004-04-01
CA2211687C (en) 2011-05-24
US6331301B1 (en) 2001-12-18
JP3297687B2 (ja) 2002-07-02
CN1146440C (zh) 2004-04-21
JP3275024B2 (ja) 2002-04-15

Similar Documents

Publication Publication Date Title
PT814827E (pt) Factor de crescimento vascular endotelial-b
EP0956339A4 (de) Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d)
TR199901971T2 (xx) Bir resept�re ba�lanan peptidler ve bile�ikler.
DE69435096D1 (de) Zusammensetzung zur in vivo erzeugung von therapeutischen produkten
ES2141761T3 (es) Secuencias de dna codificantes de nuevos factores de crecimiento/diferenciacion.
ES2142953T3 (es) Factor de crecimiento y diferenciacion de la familia del tgf-beta.
DK1356052T3 (da) Produktion af hele antistoffer i prokaryotiske celler
AU2002305450A1 (en) Proteomimetic compounds and methods
BR9711795A (pt) Peptìdeos tendo propriedades antiproliferativas
YU34196A (sh) Peptidi i jedinjenja koja se vezuju za receptor
EP2301563A3 (de) HSP20 Peptide
RU2001104349A (ru) Композиции и способы для терапии и диагностики рака предстательной железы
DK0556345T3 (da) Retrovirale vektorer,som er egnede til genterapi
ATE190352T1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
ZA87141B (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
DE60143818D1 (de) Alpha-fetoprotein-peptide und ihre verwendung
ATE235551T1 (de) Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen
ATE205531T1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
GB0004576D0 (en) Proteins
WO2001025437A3 (en) Growth factor polypeptides and nucleic acids encoding same
BG105682A (en) Bone stimulating factor
ATE414776T1 (de) Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
RU2003100172A (ru) Способ терапии инфаркта миокарда
WO2001010382A3 (en) Compositions and methods related to claudin-7
ES2147032T3 (es) Peptidos antitromboticos derivados de elementos repetidos de fibronectina tipo ii.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970926

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19990924

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20000222

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: LICENTIA LTD.

Owner name: LUDWIG INSTITUTE FOR CANCER RESEARCH

AK Designated contracting states

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69629181

Country of ref document: DE

Date of ref document: 20030828

Kind code of ref document: P

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BRAUN & PARTNER PATENT-, MARKEN-, RECHTSANWAELTE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20030404355

Country of ref document: GR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2202432

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20040426

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20070116

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20070119

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20070124

Year of fee payment: 12

Ref country code: ES

Payment date: 20070124

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20070330

Year of fee payment: 12

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20080901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080331

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080901

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20080303

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20081002

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080303

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080301

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20120321

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FI

Payment date: 20120321

Year of fee payment: 17

Ref country code: IT

Payment date: 20120324

Year of fee payment: 17

Ref country code: DK

Payment date: 20120326

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20120327

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20120321

Year of fee payment: 17

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20131001

REG Reference to a national code

Ref country code: DK

Effective date: 20130331

Ref legal event code: EBP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130301

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 245437

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130301

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130301

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131001

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130331

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20150324

Year of fee payment: 20

Ref country code: CH

Payment date: 20150325

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20150319

Year of fee payment: 20

Ref country code: SE

Payment date: 20150324

Year of fee payment: 20

Ref country code: GB

Payment date: 20150324

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20150318

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69629181

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20160229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20160229

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG